2.29

4.18% -0.10

After Hours: 2.29

Nuvation Bio Inc (NUVB)

Overview News Price History Option Chain Discussions Forecast

Nuvation Bio Inc stock is traded at $2.29, with a volume of 2.56M. It is down -4.18% in the last 24 hours and down -28.88% over the past month. Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Previous Close:

$2.39

Open:

$2.38

24h Volume:

2.56M

Relative Volume:

1.55

Market Cap:

$781.71M

Revenue:

Net Income/Loss:

$-75.80M

P/E Ratio:

-5.5854

EPS:

-0.41

Net Cash Flow:

$-68.07M

1W Performance:

-16.42%

1M Performance:

-28.88%

6M Performance:

-37.09%

1Y Performance:

+70.90%

1-Day Range:

$2.28

$2.45

1-Week Range:

$2.28

$2.76

52-Week Range:

$0.95

$4.1598

Nuvation Bio Inc Stock (NUVB) Company Profile

Name

Nuvation Bio Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(415) 754-3517

Address

357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO

Employee

167

Twitter

Next Earnings Date

2024-08-01

Latest SEC Filings

NUVB's Discussions on Twitter

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-06-23	Downgrade	Jefferies	Buy → Hold
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
May-04-22	Initiated	H.C. Wainwright	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Apr-06-21	Initiated	RBC Capital Mkts	Outperform
Mar-08-21	Initiated	BMO Capital Markets	Outperform
Mar-08-21	Initiated	BTIG Research	Buy
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	Jefferies	Buy
Mar-08-21	Initiated	Wedbush	Outperform

View All

Nuvation Bio Inc Stock (NUVB) Latest News

09:51 AM

Ratio Review: Analyzing Nuvation Bio Inc (NUVB)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

09:51 AM

06:04 AM

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Sep 24, 2024

Sep 23, 2024

Jefferies Upgrades Nuvation Bio Inc (NUVB) to a Buy from a Hold - Knox Daily

Sep 23, 2024

Metric Analysis: Nuvation Bio Inc (NUVB)’s Key Ratios in the Limelight - The Dwinnex

Sep 23, 2024

Tissue therapy company broadens reach in UK market - The Business Desk

Sep 23, 2024

Rhumbline Advisers Grows Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

Sep 23, 2024

Sep 21, 2024

15,695 Shares in Nuvalent, Inc. (NASDAQ:NUVL) Purchased by Edgestream Partners L.P. - MarketBeat

Sep 21, 2024

Sep 20, 2024

Upstream enters IPO queue; Nuvalent follow-on balloons to $575M - BioCentury

Sep 20, 2024

WINTON GROUP Ltd Purchases New Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Sep 20, 2024

Sep 19, 2024

NUVB: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle

Sep 19, 2024